Navigation Links
Campbell Alliance to Moderate Senior-Level Panel Discussion at Windhover Pharmaceutical Strategic Alliances Conference
Date:9/21/2007

RALEIGH, N.C., Sept. 21 /PRNewswire/ -- Campbell Alliance, the leading management consulting firm specializing in the pharmaceutical and biotech industries, today announced that Ben Bonifant, Vice President and head of Campbell's Business Development practice, will moderate a panel discussion at the Pharmaceutical Strategic Alliances (PSA) conference hosted by Windhover Information. The conference will be held September 25-27, 2007 at The Marriott Financial Center in New York City.

The panel discussion, titled "Comparing the Long-Term Optimism of Platform Technologies to the Immediate Market Opportunities of Late-Stage Products," will explore whether a new technology needs to be demonstrated through the advancement of a late-stage product before a potential suitor is willing to discuss a deal. Scheduled for September 25 at 4:30 p.m., the panel will include participation from four senior-level industry executives with experience negotiating both platform technology and late-stage product deals. Mr. Bonifant will open the panel with a brief analysis of deal trends over the past 10 years involving platform technologies and late-stage products, as well as those deals that eventually advanced to an outright acquisition of the out- licensing company. The panel will then move into an interactive question and answer session.

"Over the past 10 years it has been interesting to watch the licensing environment for pharma and biotech products move from one that was very much in favor of licensing early-stage platform technologies to one that found the need wait until a technology was proven through the advancement of a derived compound to phase 2 or phase 3 of development," stated Bonifant. "In the past 18 months we've seen a resurgence of interest in platforms, with several development deals coming to fruition. Some notable deals even started as previous single-product relationships surrounding an innovative technology and resulted in outright acquisitions just recently. Clearly, a factor driving the acquisition of several platform companies has been the recognition within large pharma companies of a need to build out their biologics capabilities," he continued.

Mr. Bonifant has been a management consultant for nearly 15 years, helping leaders of global pharmaceuticals and biotechnology organizations and decision makers in large private equity funds. His perspectives on developments in the life sciences market are frequently published in industry and strategy journals, and he is a frequent guest lecturer at some of the nation's premier universities. Mr. Bonifant earned an MBA from the Stanford Graduate School of Business.

For more information on Windhover's Pharmaceutical Strategic Alliances conference, please visit http://www.windhover.com/psa.

About the Business Development Practice at Campbell Alliance

The Business Development Practice at Campbell Alliance helps licensing executives achieve an edge over the competition. Our consultants provide experienced counsel to clients who need assistance developing business development strategies, identifying partners, prioritizing targets, evaluating opportunities, and negotiating deals.

The firm's team includes seasoned consultants and industry professionals in pharmaceutical and biotech business development who have identified, assessed, and executed numerous in-licensing deals. They have also been valuable in aiding out-licensors, helping clients improve internal processes for pharmaceutical business development, and assisting top executives chart new strategies in corporate development.

About Campbell Alliance

Campbell Alliance is the leading management consulting firm specializing in the pharmaceutical and biotechnology industries. The firm's clients include most of the world's top 20 pharmaceutical companies, as well as numerous emerging and midsize firms. Campbell Alliance is organized into practice areas, each specializing in a critical industry function, including Brand Management, Business Development, Clinical Development, Managed Markets, and Sales. From its locations in Raleigh, N.C., Parsippany, N.J., Los Angeles, San Francisco, Chicago, Boston, Philadelphia, New York City, and Atlanta, the firm serves clients throughout North America, Europe, and Japan. For more information on Campbell Alliance, please visit http://www.campbellalliance.com.

CONTACT:

James Forte

Director, Public and Media Relations

Campbell Alliance

919-844-7100, extension 7195

jforte@campbellalliance.com


'/>"/>
SOURCE Campbell Alliance
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Biomedical Alliance about more than stem cells
2. Doyle seeks $2.5M for biomedical alliance
3. Alliance looks to create the right chemistry in SE Wisconsin
4. Biomedical alliance marks first full year
5. New alliance to provide Wi-Fi network for City of Madison
6. Budget axe could cut SE Wisconsin tech alliance funding
7. Biotech Alliance pushes ahead in SE Wisconsin with likely state funding
8. Milwaukee research alliance sees need for incubator
9. University alliance gets $2.5 million to encourage minorities in science and technology
10. Suite Scheduler Announces Alliance with Ice Technologies
11. Alliance Brings E-Business Technologies to Wisconsin Manufacturers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)...  The Prostate Cancer Foundation (PCF) is pleased to announce 24 ... for prostate cancer. Members of the Class of 2016 were selected from a ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking software ... State Crime Laboratory, has joined STACS DNA as a Field Application Specialist. , ... Tremblay, President and COO of STACS DNA. “In further expanding our capacity as a ...
(Date:6/23/2016)... , June 23, 2016 ... Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... , the peer-reviewed journal from touchONCOLOGY, Andrew ... escalating cost of cancer care is placing an ... result of expensive biologic therapies. With the patents ...
(Date:6/23/2016)... Connecticut (PRWEB) , ... June 23, 2016 , ... ... introduce a new line of intelligent tools designed, tuned and optimized exclusively for ... September 12–17 in Chicago. The result of a collaboration among several companies with ...
Breaking Biology Technology:
(Date:6/9/2016)... attendance control systems is proud to announce the introduction of fingerprint attendance control software, ... employees are actually signing in, and to even control the opening of doors. ... ... ... Photo - http://photos.prnewswire.com/prnh/20160609/377487 ...
(Date:6/2/2016)... , June 2, 2016 The Department ... has awarded the 44 million US Dollar project, for the ... Vehicle Plates including Personalization, Enrolment, and IT Infrastructure , ... in the production and implementation of Identity Management Solutions. Numerous ... however Decatur was selected for the ...
(Date:5/24/2016)... Ampronix facilitates superior patient care by providing unparalleled technology to leaders of ... the latest premium product recently added to the range of products distributed by Ampronix. ... ... ... Medical Display- Ampronix News ...
Breaking Biology News(10 mins):